Phreesia (PHR) 10-Q 10 Dec 19 2020 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Oct. 31, 2019	Dec. 06, 2019
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Entity Registrant Name	Phreesia, Inc.
Entity Central Index Key	0001412408
Document Period End Date	Oct. 31, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--01-31
Trading Symbol	PHR
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Address, State or Province	NY
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		35,885,084

Balance sheets

Balance sheets - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019
Current:
Cash and cash equivalents	$ 91,389	$ 1,543
Settlement assets	10,384	10,217
Accounts receivable, net of allowance for doubtful accounts of $729 and $517	20,008	16,109
Deferred contract acquisition costs	1,631	1,673
Prepaid expenses	5,287	3,340
Total current assets	128,699	32,882
Property and equipment, net of accumulated depreciation and amortization of $34,304 and $27,862	14,364	14,211
Capitalized internal-use software, net of accumulated amortization of $18,266 and $14,621	8,501	7,816
Deferred contract acquisition costs	1,512	1,521
Intangible assets, net of accumulated amortization of $212 and $33	1,258	1,437
Goodwill	251	250
Other assets	1,324	1,145
Total assets	155,909	59,262
Current:
Settlement obligations	10,384	10,217
Current portion of long-term debt	0	97
Current portion of capital leases	2,413	1,869
Accounts payable	5,949	4,160
Accrued expenses	8,018	5,098
Deferred revenue	5,326	6,488
Total current liabilities	32,090	27,929
Long-term debt, net of current portion	19,355	27,918
Capital leases, net of current portion	1,971	2,401
Warrant liability	0	5,498
Total liabilities	53,416	63,746
Commitments and contingencies (Note 12)
Redeemable preferred stock:
Redeemable preferred stock value	0	206,490
Stockholders' Equity (Deficit):
Common stock, $0.01 par value - 500,000,000 and 80,000,000 shares authorized as of October 31, 2019 and January 31, 2019, respectively; 35,759,355 and 1,994,721 shares issued and outstanding as of October 31, 2019 and January 31, 2019, respectively	359	20
Additional paid-in capital	382,951	0
Accumulated deficit	(280,817)	(210,994)
Total stockholders' equity (deficit)	102,493	(210,974)
Total Liabilities, Redeemable Preferred Stock and Stockholders' Equity (Deficit)	155,909	59,262
Senior A Redeemable Preferred Stock [Member]
Redeemable preferred stock:
Redeemable preferred stock value	0	79,311
Series B Redeemable Convertible Preferred Stock [Member]
Redeemable preferred stock:
Redeemable preferred stock value	0	51,872
Junior Convertible Preferred Stock [Member]
Redeemable preferred stock:
Redeemable preferred stock value	0	32,746
Redeemable Preferred Stock [Member]
Redeemable preferred stock:
Redeemable preferred stock value	$ 0	$ 42,561

Balance sheets (Parenthetical)

Balance sheets (Parenthetical) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019
Allowance for doubtful accounts	$ 729	$ 517
Accumulated depreciation and amortization, Property and equipment	34,304	27,862
Accumulated amortization, Capitalized internal-use software	18,266	14,621
Accumulated amortization, Intangible assets	$ 212	$ 33
Common stock, par or stated value per share	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	80,000,000
Common stock, shares issued	35,872,057	1,994,721
Common stock, shares outstanding	35,872,057	1,994,721
Senior A Redeemable Preferred Stock [Member]
Temporary equity, par or stated value per share		$ 0.01
Temporary equity, shares authorized	0	14,500,000
Temporary equity, shares issued	0	13,674,365
Temporary equity, shares outstanding	0	13,674,365
Series B Redeemable Convertible Preferred Stock [Member]
Temporary equity, par or stated value per share		$ 0.01
Temporary equity, shares authorized	0	10,820,169
Temporary equity, shares issued	0	9,197,142
Temporary equity, shares outstanding	0	9,197,142
Junior Convertible Preferred Stock [Member]
Temporary equity, par or stated value per share		$ 0.01
Temporary equity, shares authorized	0	34,000,000
Temporary equity, shares issued	0	32,746,041
Temporary equity, shares outstanding	0	32,746,041
Redeemable Preferred Stock [Member]
Temporary equity, par or stated value per share		$ 0.01
Temporary equity, shares authorized	0	44,000,000
Temporary equity, shares issued	0	42,560,530
Temporary equity, shares outstanding	0	42,560,530

Statements of operations

Statements of operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018
Revenue:
Revenues	$ 32,843	$ 24,756	$ 91,968	$ 73,406
Expenses:
Cost of revenue (excluding depreciation and amortization)	4,388	3,805	12,594	10,632
Payment processing expense	6,902	5,393	20,952	16,309
Sales and marketing	8,348	7,195	24,170	19,971
Research and development	4,774	3,856	13,762	10,144
General and administrative	7,184	4,540	20,849	14,118
Depreciation	2,153	1,966	6,444	5,515
Amortization	1,325	1,037	3,823	2,912
Total expenses	35,074	27,792	102,594	79,601
Operating loss	(2,231)	(3,036)	(10,626)	(6,195)
Other income (expense)	77	203	(740)	167
Change in fair value of warrant liability	0	(611)	(3,307)	(1,496)
Interest income (expense)	(219)	(728)	(1,769)	(2,459)
Total other income (expense)	(142)	(1,136)	(5,816)	(3,788)
Loss before provision for income taxes	(2,373)	(4,172)	(16,442)	(9,983)
Provision for income taxes	(64)	0	(183)	0
Net loss	(2,437)	(4,172)	(16,625)	(9,983)
Preferred stock dividend paid	0	0	(14,955)	0
Accretion of redeemable preferred stock	0	(9,236)	(56,175)	(20,962)
Net loss attributable to common stockholders, basic and diluted	$ (2,437)	$ (13,408)	$ (87,755)	$ (30,945)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.07)	$ (7.02)	$ (5.85)	$ (26.30)
Weighted-average common shares outstanding, basic and diluted	35,790,951	1,909,858	15,007,247	1,176,833
Subscription And Related Services [Member]
Revenue:
Revenues	$ 14,606	$ 10,929	$ 41,292	$ 31,391
Payment Processing Fees [Member]
Revenue:
Revenues	11,559	9,073	34,781	27,478
Life Sciences [Member]
Revenue:
Revenues	$ 6,678	$ 4,754	$ 15,895	$ 14,537

Statements of redeemable prefer

Statements of redeemable preferred stock and stockholders' equity (deficit) - USD ($) $ in Thousands	Total	Redeemable Series A Preferred Stock [Member]	Redeemable Series B Preferred Stock [Member]	Junior Convertible Preferred Stock [Member]	Redeemable Preferred Stock [Member]	Total Redeemable Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Beginning Balance at Jan. 31, 2018		$ 57,022	$ 43,962	$ 32,746	$ 42,561	$ 176,291
Beginning Balance at Jan. 31, 2018	$ (167,683)						$ 16	$ 0	$ (167,699)
Beginning Balance, Shares at Jan. 31, 2018		13,674,365	9,197,142	32,746,041	42,560,530
Beginning Balance, Shares at Jan. 31, 2018							1,638,331
Net loss	(3,224)								(3,224)
Stock-based compensation expense	252							252
Exercise of stock options	146						$ 1	145
Exercise of stock options Shares							131,560
Accretion of redeemable preferred stock		$ 1,406	$ 1,084			2,490
Accretion of redeemable preferred stock	(2,490)							(397)	(2,093)
Ending Balance at Apr. 30, 2018		$ 58,428	$ 45,046	$ 32,746	$ 42,561	178,781
Ending Balance at Apr. 30, 2018	(172,999)						$ 17	0	(173,016)
Ending Balance, Shares at Apr. 30, 2018		13,674,365	9,197,142	32,746,041	42,560,530
Ending Balance, Shares at Apr. 30, 2018							1,769,891
Beginning Balance at Jan. 31, 2018		$ 57,022	$ 43,962	$ 32,746	$ 42,561	176,291
Beginning Balance at Jan. 31, 2018	(167,683)						$ 16	0	(167,699)
Beginning Balance, Shares at Jan. 31, 2018		13,674,365	9,197,142	32,746,041	42,560,530
Beginning Balance, Shares at Jan. 31, 2018							1,638,331
Net loss	(9,983)
Cashless Exercise Of Common Stock Warrants	0
Ending Balance at Oct. 31, 2018	197,353	$ 72,350	$ 49,596	$ 32,746	$ 42,561	197,253			197,372
Ending Balance at Oct. 31, 2018							$ 19
Ending Balance, Shares at Oct. 31, 2018		13,674,365	9,197,142	32,746,041	42,560,782
Ending Balance, Shares at Oct. 31, 2018							1,944,445
Beginning Balance at Apr. 30, 2018		$ 58,428	$ 45,046	$ 32,746	$ 42,561	178,781
Beginning Balance at Apr. 30, 2018	(172,999)						$ 17	0	(173,016)
Beginning Balance, Shares at Apr. 30, 2018		13,674,365	9,197,142	32,746,041	42,560,530
Beginning Balance, Shares at Apr. 30, 2018							1,769,891
Net loss	(2,587)								(2,587)
Stock-based compensation expense	252							252
Exercise of stock options	12							12
Exercise of stock options Shares							16,057
Accretion of redeemable preferred stock		$ 6,961	$ 2,275			9,236
Accretion of redeemable preferred stock	(9,236)							(264)	(8,972)
Ending Balance at Jul. 31, 2018		$ 65,389	$ 47,321	$ 32,746	$ 42,561	188,017
Ending Balance at Jul. 31, 2018	(184,558)						$ 17	0	(184,575)
Ending Balance, Shares at Jul. 31, 2018		13,674,365	9,197,142	32,746,041	42,560,782
Ending Balance, Shares at Jul. 31, 2018							1,785,948
Net loss	(4,172)								(4,172)
Stock-based compensation expense	447							447
Exercise of stock options	166						$ 2	164
Exercise of stock options Shares							158,497
Accretion of redeemable preferred stock		$ 6,961	$ 2,275			9,236
Accretion of redeemable preferred stock	(9,236)							(611)	(8,625)
Ending Balance at Oct. 31, 2018	197,353	$ 72,350	$ 49,596	$ 32,746	$ 42,561	197,253			197,372
Ending Balance at Oct. 31, 2018							$ 19
Ending Balance, Shares at Oct. 31, 2018		13,674,365	9,197,142	32,746,041	42,560,782
Ending Balance, Shares at Oct. 31, 2018							1,944,445
Beginning Balance at Jan. 31, 2019	206,490	$ 79,311	$ 51,872	$ 32,746	$ 42,561	206,490
Beginning Balance at Jan. 31, 2019	(210,974)						$ 20	0	(210,994)
Beginning Balance, Shares at Jan. 31, 2019		13,674,365	9,197,142	32,746,041	42,560,530
Beginning Balance, Shares at Jan. 31, 2019							1,994,721
Net loss	(6,695)								(6,695)
Stock-based compensation expense	599							599
Exercise of stock options	37						$ 0	37
Exercise of stock options Shares							29,798
Issuance of common stock warrants	833							833
Accretion of redeemable preferred stock		$ 5,196	$ 2,667			7,863
Accretion of redeemable preferred stock	(7,863)							(1,469)	(6,394)
Ending Balance at Apr. 30, 2019		$ 84,507	$ 54,539	$ 32,746	$ 42,561	214,353
Ending Balance at Apr. 30, 2019	(224,063)						$ 20	0	(224,082)
Ending Balance, Shares at Apr. 30, 2019		13,674,365	9,197,142	32,746,041	42,560,530
Ending Balance, Shares at Apr. 30, 2019							2,024,519
Beginning Balance at Jan. 31, 2019	206,490	$ 79,311	$ 51,872	$ 32,746	$ 42,561	206,490
Beginning Balance at Jan. 31, 2019	(210,974)						$ 20	0	(210,994)
Beginning Balance, Shares at Jan. 31, 2019		13,674,365	9,197,142	32,746,041	42,560,530
Beginning Balance, Shares at Jan. 31, 2019							1,994,721
Net loss	(16,625)
Cashless Exercise Of Common Stock Warrants	2,521
Ending Balance at Oct. 31, 2019	0		$ 0	$ 0	$ 0
Ending Balance at Oct. 31, 2019	102,493						$ 359	382,951	(280,817)
Ending Balance, Shares at Oct. 31, 2019			0	0	0
Ending Balance, Shares at Oct. 31, 2019							35,872,057
Beginning Balance at Apr. 30, 2019		$ 84,507	$ 54,539	$ 32,746	$ 42,561	214,353
Beginning Balance at Apr. 30, 2019	(224,063)						$ 20	0	(224,082)
Beginning Balance, Shares at Apr. 30, 2019		13,674,365	9,197,142	32,746,041	42,560,530
Beginning Balance, Shares at Apr. 30, 2019							2,024,519
Net loss	(7,493)								(7,493)
Stock-based compensation expense	1,467							1,467
Exercise of stock options	41						$ 0	41
Exercise of stock options Shares							22,038
Accretion of redeemable preferred stock		$ 27,510	$ 20,802			48,312
Accretion of redeemable preferred stock	(48,312)							(1,508)	(46,804)
Payment of preferred stock dividends	(14,955)							(14,955)
Issuance of common stock in initial public offering, net of issuance costs of $6,083,648	124,697						$ 78	124,619
Issuance of common stock in initial public offering, net of issuance costs of $6,083,648 Shares							7,812,500
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock	262,665	$ (112,018)	$ (75,341)	$ (32,746)	$ (42,561)	(262,665)	$ 253	262,412
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock Shares		(13,674,365)	(9,197,142)	(32,746,041)	(42,560,530)		25,311,535
Conversion and exercise of preferred stock warrants into common stock	8,805						$ 6	8,799
Conversion and exercise of preferred stock warrants into common stock Shares							588,763
Ending Balance at Jul. 31, 2019		$ 0	$ 0	$ 0	$ 0	$ 0
Ending Balance at Jul. 31, 2019	102,852						$ 357	380,875	(278,380)
Ending Balance, Shares at Jul. 31, 2019		0	0	0	0
Ending Balance, Shares at Jul. 31, 2019							35,759,355
Net loss	(2,437)								(2,437)
Stock-based compensation expense	1,766							1,766
Exercise of stock options	366						$ 1	365
Exercise of stock options Shares							59,679
Cashless Exercise Of Common Stock Warrants	2						$ 1	1
Cashless exercise of common stock warrants Shares							53,023
Deferred offering costs	(56)							(56)
Ending Balance at Oct. 31, 2019	0		$ 0	$ 0	$ 0
Ending Balance at Oct. 31, 2019	$ 102,493						$ 359	$ 382,951	$ (280,817)
Ending Balance, Shares at Oct. 31, 2019			0	0	0
Ending Balance, Shares at Oct. 31, 2019							35,872,057

Statements of redeemable pref_2

Statements of redeemable preferred stock and stockholders' equity (deficit) (Parenthetical) - USD ($) $ in Thousands	Jul. 31, 2019	Jul. 22, 2019
Statement of Stockholders' Equity [Abstract]
Deferred Offering Costs	$ 6,084	$ 6,084

Statements of cash flows

Statements of cash flows - USD ($) $ in Thousands	9 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Cash flows from operating activities:
Net loss	$ (16,625)	$ (9,983)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	10,267	8,427
Stock-based compensation expense	3,832	950
Change in fair value of warrants liability	3,307	1,496
Amortization of debt discount	412	579
Loss on extinguishment of debt	1,073	0
Cost of Phreesia hardware purchased by customers	512	0
Deferred contract acquisition costs amortization	1,465	1,179
Changes in operating assets and liabilities
Accounts receivable	(3,899)	(346)
Prepaid expenses and other assets	(2,943)	130
Deferred contract acquisition costs	(1,414)	(1,468)
Accounts payable	1,629	1,208
Accrued expenses	3,098	(145)
Deferred revenue	(1,162)	(359)
Net cash provided by (used in) operating activities	(448)	1,668
Cash flows used in investing activities:
Capitalized internal-use software	(4,329)	(3,744)
Purchase of property and equipment	(4,826)	(3,397)
Net cash used in investing activities	(9,155)	(7,141)
Cash flows from financing activities:
Proceeds from IPO	130,781	0
Proceeds from revolving line of credit	9,876	3,500
Payments of revolving line of credit	(17,676)	(3,500)
Proceeds from term loan	20,000	0
Repayment of term loan	(1,042)	(875)
Repayment of loan payable	(20,000)	0
Payment of preferred stock dividends	(14,955)	0
Payment on capital leases	(1,624)	(1,870)
Debt extinguishment costs	(300)	0
Debt issuance costs	(112)	0
Proceeds from issuance of common stock upon exercise of stock options	445	324
Payment of offering costs	(5,944)	0
Net cash (used in) provided by financing activities	99,449	(2,421)
Net increase (decrease) in cash and cash equivalents	89,846	(7,894)
Cash and cash equivalents – beginning of period	1,543	10,503
Cash and cash equivalents – end of period	91,389	2,609
Supplemental information:
Property and equipment acquisitions through capital leases	1,738	2,053
Deferred issuance costs included in accounts payable and accrued expenses	0	0
Purchase of property and equipment included in accounts payable	546	0
Issuance of warrants related to debt	833	0
Cashless exercise of common stock warrants	2,521	0
Cash payments for:
Interest	$ 1,834	$ 1,732

Background and liquidity

Background and liquidity	9 Months Ended
	Oct. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and liquidity	1. Background and liquidity (a) Background Phreesia, Inc. (the Company) is a leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care and enabling healthcare provider organizations to optimize operational efficiency, improve profitability and enhance clinical care. Through the SaaS-based Phreesia Platform (the Phreesia Platform), the Company offers healthcare provider organizations a robust suite of solutions to manage the patient intake process and a leading payments solution for secure processing of patient payments. The Company’s Platform also provides life sciences companies with an engagement channel for targeted and direct communication with patients. The Company was formed in May 2005, and has its corporate headquarters in New York, and operations offices in Raleigh, North Carolina and Ottawa, Canada. (b) Initial public offering On July 22, 2019, the Company closed its initial public offering (IPO), in which the Company issued and sold 7,812,500 shares of common stock at a public offering price of $18.00 per share, resulting in net proceeds of $130,781, after deducting underwriting discounts and commissions of $9,844 but before deducting deferred offering costs of $6,084. In addition to the shares of common stock sold by the Company upon the IPO, certain selling stockholders sold an aggregate of 2,868,923 shares of common stock as part of the IPO. Upon closing of the IPO, the Company’s outstanding shares of Senior A redeemable convertible preferred stock (Senior A Preferred), Senior B redeemable convertible preferred stock (Senior B Preferred, and together with the Senior A Preferred, the Senior Preferred), and the Junior convertible preferred stock (the Junior Preferred, and together with the Senior Preferred, the Convertible Preferred) automatically converted into shares of common stock and all of the outstanding shares of the Company’s redeemable preferred stock (Redeemable Preferred) were automatically extinguished and cancelled at the closing of the IPO. In addition, the Company’s warrants to purchase shares of Senior Preferred were converted into warrants to purchase shares of the Company’s common stock upon the closing of the IPO. Additionally, 588,763 shares of common stock were issued upon the cashless exercise of common stock warrants (See Note 10). Also, in connection with the IPO, the Company paid $14,955 in dividends to the Senior Preferred stockholders. (c) Recapitalization The Company effected a 0.4551-for-1 (d) Liquidity Since the Company commenced operations, it has not generated sufficient revenue to meet its operating expenses and has continued to incur significant net losses. To date, the Company has primarily relied upon the proceeds from issuances of preferred stock and debt , , and services Management believes that the Company’s cash and cash equivalents at October 31, 2019, along with cash generated in the normal course of business, and available borrowing capacity under its February 2019 Credit Facility ( See The ability of the Company to achieve successful operations will depend on, among other things, new business, the retention of customers, and the effectiveness of sales and marketing initiatives. The Company is subject to a number of risks similar to other companies in its stage of business life cycle, including dependence on key individuals, competition in the marketplace, and the need to fund future product and services development.

Basis of presentation

Basis of presentation	9 Months Ended
	Oct. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	2. Basis of presentation (a) Basis of presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) and include the accounts of Phreesia, Inc. and its branch operation in Canada. (b) Fiscal year The Company’s fiscal year ends on January 31. References to fiscal 2018 and 2019 refer to the fiscal year ended January 31, 2018 and 2019, respectively. (c) Unaudited interim financial statements The accompanying financial statements and the related footnote disclosures are unaudited. The unaudited interim financial statements have been prepared on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for the fair statement of the Company’s interim financial position as of October 31, 2019 and the results of its operations and its cash flows for the periods ended October 31, 2019 and 2018. The results for the interim periods are not necessarily indicative of results to be expected for the full year, any other interim periods, or any future year or period. The Company’s management believes that the disclosures are adequate to make the information presented not misleading when read in conjunction with the audited financial statements and accompanying notes for the year ended January 31, 2019.

Summary of significant accounti

Summary of significant accounting policies	9 Months Ended
	Oct. 31, 2019
Accounting Policies [Abstract]
Summary of significant accounting policies	3. Summary of significant accounting policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended January 31, 2019. Since the date of those audited financial statements, there have been no changes to the Company’s significant accounting policies, including the status of recent accounting pronouncements, other than those detailed below. (a) Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments. Although management believes its estimates and assumptions are reasonable under the circumstances at the time they are made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Actual results may differ from those estimates made under different assumptions or circumstances. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use (b) Concentrations of credit risk Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one or two business days to settle which mitigates the associated risk of concentration. The Company has one third-party payment processor. The Company’s customers are primarily physician’s offices located in the United States and pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the three and nine months ended October 31, 2019 and 2018. (c) New accounting pronouncements Recent accounting pronouncements not yet adopted In August 2018, the FASB issued ASU No. 2018-13, : Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-13). 2018-13 In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, internal-use In February 2016, the FASB issued ASU 2016-02, Leases right-of-use 20 use-of-hindsight

Composition of certain financia

Composition of certain financial statement captions	9 Months Ended
	Oct. 31, 2019
Composition Of Certain Financial Statement [Abstract]
Composition of certain financial statement captions	4. Composition of certain financial statement captions (a) Accrued expenses Accrued expenses as of October 31, 2019 and January 31, 2019 are as follows: October 31, January 31, 2019 2019 Payment processing fees liability $ 2,428 $ 2,267 Commission and bonus 2,653 320 Accrued payment related to acquisition of Vital Score 350 350 Vacation 543 417 Other 2,044 1,744 Total $ 8,018 $ 5,098 (b) Property and equipment Property and equipment as of October 31, 2019 and January 31, 2019 are as follows: Useful Life (years) 31 2019 2019 PhreesiaPads and Arrivals Stations 3 $ 26,470 $ 22,747 Computer equipment 3 17,093 14,338 Computer software 3 2,223 2,166 Hardware development 3 1,024 1,024 Furniture and fixtures 7 683 647 Leasehold improvements 2 1,175 1,151 Total property and equipment $ 48,668 $ 42,073 Less accumulated depreciation and amortization (34,304 ) (27,862 ) Property and equipment — net $ 14,364 $ 14,211 Depreciation expense related to property and equipment amounted to $2,153 and $1,966 for the three months ended October 31, 2019 and 2018, respectively. Depreciation expense related to property and equipment amounted to $6,444 and $5,515 for the nine months ended October 31, 2019 and 2018, respectively. Capital lease depreciation, included in depreciation expense, was $1,758 for the nine months ended October 31, 2019. Assets under capital leases included in computer equipment were $11,973 and $10,235 as of October 31, 2019 and January 31, 2019. Accumulated amortization of assets under capital leases was $7,127 and $5,369 as of October 31, 2019 and January 31, 2019, respectively. (c) Capitalized internal use software For the three months ended October 31, 2019 and 2018, the Company capitalized $1,452 and $1,274, respectively, of costs related to the Phreesia Platform. For the nine months ended October 31, 2019 and 2018, the Company capitalized $4,329 and $3,744 of costs related to the Phreesia Platform. During the three months ended October 31, 2019 and 2018, amortization expense of capitalized internal-use internal-use (d) Intangible assets The following presents the details of intangible assets as of October 31, 2019 and January 31, 2019. Useful Life (years) October 31, January 31, 2019 Acquired technology gross carrying value 5 $ 490 $ 490 Customer relationship gross carrying value 7 980 980 Total intangible assets $ 1,470 $ 1,470 Less accumulated amortization (212 ) (33 ) Net carrying value $ 1,258 $ 1,437 The remaining useful life for acquired technology in years is 4.1 and 4.8 as of October 31, 2019 and January 31, 2019, respectively. The remaining useful life for customer relationships in years is 6.1 and 6.8 as of October 31 Amortization expense associated with intangible assets amounted to $59 and $0 for the three months ended October 31, 2019 and 2018, respectively. Amortization expense associated with intangible assets amounted to $178 and $0 for the nine months ended October 31, 2019 and 2018, respectively. The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of October 31, 2019: 2020 (Remaining three months) $ 60 Years ending January 31, 2021 238 2022 238 2023 238 2024 224 2025 - thereafter 260 Total $ 1,258 (e) Deferred offering costs Deferred offering costs consist primarily of accounting, legal, and other fees related to the Company’s IPO. Prior to the IPO, all deferred offering costs were capitalized in other assets on the accompanying balance sheet. Upon the closing of the IPO on July 22, 2019, $6,084 were recorded in stockholders’ deficit as a reduction of additional paid in capital. An additional $56 in deferred offering costs related to the IPO were recorded in stockholders’ deficit as a reduction of paid in capital during the three months ended The Company recorded $540 of deferred offering costs within other assets on the accompanying balance sheet as of January 31, 2019. (f) Accounts receivable Accounts receivable as of October 31, 2019 and January 31, 2019 are as follows: October 31, January 31, 2019 2019 Billed $ 19,759 $ 15,990 Unbilled 978 636 Total accounts receivable, gross $ 20,737 $ 16,626 Less allowance for doubtful accounts (729 ) (517 ) Total accounts receivable $ 20,008 $ 16,109

Revenues

Revenues	9 Months Ended
	Oct. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue	5. Revenue The Company generates revenue primarily from providing an integrated SaaS-based software and payment platform for the healthcare industry. The Company derives revenue from subscription fees and related services generated from the Company’s provider customers for access to the Phreesia Platform, payment processing fees based on patient payment volume processed through the Phreesia Platform, and from digital patient engagement revenue from life sciences companies to reach, educate and communicate with patients when they are most receptive and actively seeking care. The amount of subscription and related services revenue recorded pursuant to ASC 840 for the leasing of the Company’s self-service intake tablets and onsite kiosks was $1,496 and $1,197 for the three months ended October 31, 2019 and 2018, respectively. The amount of subscription and related services revenues recorded pursuant to ASC 840 for the leasing of the Company’s self-service intake tablets and onsite kiosks was $4,462 and $3,388 for the nine months ended October 31, 2019 and 2018, respectively. Contract balances The following table represents a rollforward of contract assets and contract liabilities: Contract assets Contract January 31, 2019 $ 636 $ 6,488 Amount transferred to receivables from contract assets (576 ) — Contract asset additions 918 — Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (11,168 ) Increases due to invoicing prior to satisfaction or performance obligations — 10,006 October 31, 2019 $ 978 $ 5,326 Cost to obtain a contract The Company capitalizes certain incremental costs to obtain customer contract and amortizes these costs over the life of the contracts. Amortization expense is included in sales and marketing expenses in the accompanying statements of operations and totaled $491 and $416 for the three months ended October 31, 2019 and 2018, respectively. Amortization expense totaled $1,465 and $1,179 for the nine months ended October 31, 2019 and 2018, respectively. The Company periodically reviews these deferred contract acquisition costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented. The following table represents a rollforward of deferred contract acquisition costs: 2019 2019 Beginning balance $ 3,194 $ 2,334 Additions to deferred contract acquisition costs 1,414 2,500 Amortization of deferred contract acquisition costs (1,465 ) (1,640 ) Ending balance 3,143 3,194 Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,631 1,673 Deferred contract acquisition costs, non current 1,512 1,521 Total deferred contract acquisition costs $ 3,143 $ 3,194

Debt

Debt	9 Months Ended
	Oct. 31, 2019
Debt Disclosure [Abstract]
Debt	6. Debt As of October 31, 2019 and January 31, 2019, the Company had the following outstanding loan balances: October 31, January 31, Term loan $ 20,000 $ 1,042 Line of credit — 7,800 Loan payable — 20,000 Total debt $ 20,000 $ 28,842 Less current maturities — (97 ) Less deferred financing costs (983 ) (996 ) Plus accrued interest 121 — Plus accrued final payment 217 169 Long term debt, net of current portion $ 19,355 $ 27,918 The Company had a loan facility with a commercial bank that provided for a term loan with an original principal amount of $3,500 and a $10,000 revolving line of credit, which was later increased to $20,000. The term loan was interest only, at a floating per annum rate equal to the Prime Rate as quoted by Wall Street Journal print edition less three-quarters of one percent (0.75%), for 12 months from the date of borrowing followed by 36 monthly payments of principal and interest. The Prime Rate was 5.50% as of January 31, 2019. In addition to principal and interest payments due under the l Borrowings under the revolving line of credit bore interest at the prime rate plus 1.00% and were limited to the greater of $20,000 or an amount determined pursuant to a borrowing base. The revolving credit facility had a maturity date of November 2019. Borrowings under this facility were collateralized by substantially all of the assets of the Company and the Company was required to comply with certain financial covenants related to this facility. The Company was in compliance with all covenants related to the revolving line of credit as of January 31, 2019 and until the total balance of $17,676 was fully repaid on July 22, 2019 with proceeds from the IPO. Weighted-average borrowings outstanding under the revolving line of credit were $979 and $971 for the nine months ended October 31, 2019 and 2018, respectively. Interest expense under the revolving line of credit was $0 and $ 42 including amortization of deferred financing costs of $0 and $18, for the three months ended October 31, 2019 and 2018, respectively. Interest expense under the revolving line of credit was $166 and $115 including amortization of deferred financing costs of $13 and $53, for the nine months ended October 31, 2019 and 2018, respectively. On November 7, 2016, the Company entered into a 5-year On February 28, 2019 (the Effective Date), the Company entered into an Amended and Restated Loan and Security Agreement (the New Loan Agreement) that provides for a $20,000 term loan and a revolving credit facility with up to $25,000 of availability. The proceeds from the New Loan Agreement were used to repay in full the term loan, which had a balance of $1,042 as of January 31, 2019 and the $20,000 outstanding under the Loans Payable. The Company is also permitted to borrow an additional $10,000 term loan (the Term Loan B Advance) and, subject to the bank’s approval, another $15,000 (the Term Loan C Advance) prior to February 28, 2020. The term loans under the New Loan Agreement bear interest, which is payable monthly, at a floating rate equal to the bank’s prime rate plus 1.50% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the prime plus 0.75%. Principal payments due under the term loans are due in 36 equal monthly installments beginning in March 2021. In addition to principal and interest payments due under the term loans, the Company is required to make a final payment to the lenders due upon the earlier of prepayment or maturity of the term loan, which is equal to 2.75% of the original principal amount. The Company accrues the estimated final payment fee using the effective interest method resulting in a charge to interest expense of $217 for the nine months ended October 31, 2019. In connection with the New Loan Agreement, the Company issued warrants to the lenders to purchase an aggregate of 150,274 shares of common stock at an exercise price of $8.02 per share. The w The Company accounted for the settlement of the Loans Payable and the term loan as a debt extinguishment and recorded an expense of $1,073, which is included in other income (expense), and is comprised of the write-off Borrowings under the revolving credit facility are subject to a borrowing base equal to 80% of eligible accounts receivable plus a percentage of recurring revenue, as defined, not to exceed $25,000 in the aggregate. The Company has $25,000 of availability as of October 31, 2019. Borrowings under the revolving credit facility bear interest, which is payable monthly, at a floating rate equal to the greater of the bank’s prime rate less 0.50%, or 5.0% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the greater of prime less 0.75%, or 4.75%. In addition to principal and interest due under the revolving credit facility, the Company is required to pay an annual fee of $100 per year during the first three years of the facility and then $75 per year in years four and five. Amortization of deferred financing fees N L A D The Company’s obligations under the New Loan Agreement are secured by a first priority security interest in substantially all of its assets, other than intellectual property. The New Loan Agreement includes a financial covenant that requires the Company to achieve specified revenue levels, as defined, through January 31, 2020, after which time revenue levels for covenants purposes will be determined by the bank based on the Company’s forecast, subject to certain minimums. The Company is also required to maintain certain liquidity levels, as defined. The Company was in compliance with all covenants related to the New Loan Agreement as of October 31, 2019. The New Loan Agreement contains events of default, including, without limitation, events of default upon: (i) failure to make payment pursuant to the terms of the agreement; (ii) violation of covenants; (iii) material adverse changes to the Company’s business; (iv) attachment or levy on the Company’s assets or judicial restraint on its business; (v) insolvency; (vi) significant judgments, orders or decrees for payments by the Company not covered by insurance; (vii) incorrectness of representations and warranties; (viii) incurrence of subordinated debt; (ix) revocation of governmental approvals necessary for the Company to conduct its business; and (x) failure by the Company to maintain a valid and perfected lien on the collateral securing the borrowing. As of October 31, 2019, the Company’s long-term debt is payable as follows: 2020 (Remaining three months) $ — Year ending January 31, 2021 — 2022 6,111 2023 6,667 2024 6,667 2025 - thereafter 555 Total long-term debt payment s $ 20,000

Common stock

Common stock	9 Months Ended
	Oct. 31, 2019
Common Stock [Member]
Common Stock [Line Items]
Common stock	7. Common Stock The Company closed an IPO on July 22, 2019 and filed an A R C I Upon completion of the IPO, the Company issued and sold 7,812,500 shares of common stock at an issuance price of $18.00 per share resulting in net proceeds of $130,781, after deducting underwriting discounts and commissions. In addition, all outstanding shares of Convertible Preferred stock converted into 25,311,515 shares of common stock (See Note 8) and the Company issued 588,763 shares of common stock as a result of the cashless exercise of warrants (See Note 10). An additional 53,023 shares of common stock were issued as a result of the cashless exercise of warrants as of October 31, 2019 (See Note 10).

Preferred stock

Preferred stock	9 Months Ended
	Oct. 31, 2019
Preferred Stock [Abstract]
Preferred stock	8. Preferred stock Upon completion of the IPO on July 22, 2019, all of the Company’s then outstanding shares of Senior Preferred and Junior Preferred stock automatically converted into an aggregate of 25,311,515 shares of common stock and all of the Company’s then outstanding 42,560,530 shares of redeemable preferred stock were cancelled. As of October 31, 2019, there were no shares of convertible or redeemable preferred stock issued and outstanding. In connection with the IPO, the Company’s Amended and Restated Certificate of Incorporation became effective, which authorized 20,000,000 shares of undesignated preferred stock with a par value of $0.01 per share. Preferred stock dividends of $14,955 were paid in connection with the IPO.

Equity-based compensation

Equity-based compensation	9 Months Ended
	Oct. 31, 2019
Share-based Payment Arrangement [Abstract]
Equity-based compensation	9. Equity-based compensation (a) Stock options In 2006, the Board of Directors adopted the Company’s 2006 Stock Option Plan, which provided for the issuance of options to purchase up to 151,548 shares of the Company’s common stock to officers, directors, employees, and consultants. Over the years, the Company amended the plan to increase the shares available for issuance. On October 14, 2014, the Company increased the number of shares available for issuance under the 2006 plan to 4,424,986. The 2006 Stock Option Plan expired in August 2017. In January 2018, the Board of Directors adopted the Company’s 2018 Stock Option Plan (as amended), which currently provides for the issuance of additional options to purchase up to 3,048,490 shares of the Company’s common stock to officers, directors, employees, and consultants. The option exercise price per share is determined by the Board of Directors based on the estimated fair value of the Company’s common stock. In June 2019, the Board of Directors adopted the Company’s 2019 Stock Option and Incentive Plan, which replaced the 2018 Plan upon the completion of the IPO. The 2019 Plan allows the Compensation Committee to make equity-based incentive awards to the Company’s officers, employees, directors, and consultants. The initial reserve for the issuance of awards under this Plan is 2,139,683 shares of common stock. The initial number of shares reserved and available for issuance will automatically increase on February 1, 2020 and each February 1 thereafter by 5% of the number of shares of common stock outstanding on the immediately preceding January 31 (or such lesser number of shares determined by the Compensation Committee). Options granted under the plans ha ve one-year Effective July 2019, all available shares from expired, terminated, or forfeited awards that remained under the 2006 or 2018 prior stock compensation plans will be available for grant under the 2019 Plan. In June 2019, the Board of Directors also adopted the Company’s 2019 Employee Stock Purchase Plan (The ESPP), which became effective immediately prior to the effectiveness of the registration statement for the Company’s initial public offering. The total shares of common stock initially reserved under the ESPP is limited to 855,873 shares. The fair value of stock options is estimated on the date of the grant using the Black-Scholes option pricing model for each of the stock option awards granted. The Company historically has been a private company and lacked company-specific historical and implied volatility information for shares. Accordingly, expected volatility is based on the stock volatility for comparable publicly traded companies. The Company uses the simplified method as described in S EC Staff Accounting Bullet in SAB) For the three months ended For the nine months ended October 31, October 31, October 31, October 31, 2019 2018 2019 2018 Risk-free interest rate 1.81 % 2.90 % 2.18 % 2.83 % Expected dividends None None None None Expected term (in years) 6.25 6.25 6.25 6.25 Volatility 45.90 % 45.00 % 45.15 % 45.00 % Weighted average fair market value of grants $ 12.42 $ 3.99 $ 4.99 $ 3.72 Stock option activity for the nine months ended October 31, 2019 are as follows: Number of Weighted- Weighted- Aggregate (in thousands) Outstanding 5,055,505 $ 2.45 Granted in nine months ended October 31, 2019 1,230,382 $ 8.78 Exercised (111,515 ) $ 3.98 Forfeited and expired (53,627 ) $ 3.38 Outstanding and expected to vest 6,120,745 $ 3.67 6.35 $ 140,339 Exercisable 4,197,481 $ 2.09 4.84 $ 103,178 Amount vested in nine months ended October 31, 2019 621,206 $ 4.03 As of October 31, 2019, there are 2,129,560 The aggregate intrinsic value represents the total pre-tax in-the-money For the three months ended October 31, 2019 and 2018, the Company recorded stock-based compensation expense for stock options of $809 and $447, respectively. For the nine months ended October 31, 2019 and 2018, the Company recorded stock-based compensation expense for stock options of $2,051 , Incremental expense associated with the modification of stock options during the three and nine months ended October 31, 2019 was $173. The Company has not recognized and does not expect to recognize in the foreseeable future, any tax benefit related to employee stock-based compensation expense. (b) Restricted stock units On March 25, 2019 and June 20, 2019, the Company issued 390,794 and 58,589 stock units, respectively, to employees and directors that vest based on both a time-based condition and a performance-based condition. Pursuant to the time-based condition, 10% of the restricted stock units vest after one year, 20% vest after two years, 30% vest after three years and 40% vest after four years. The performance-based condition is based on a sale of the Company or an IPO, as defined. The restricted stock units expire seven years from the grant date . Upon completion of the Company’s IPO in July 2019, the Company immediately recognized the fair value of the vested units with the unvested portion recognized over the remaining service period. In addition, in August 2019, the Company approved allowing executive officers the ability to elect to receive all or a portion of the bonus (based on its target bonus opportunity for the last half of the fiscal year) in the form of restricted stock units instead of cash. For such executive officers that elected to receive restricted stock units, such award was granted immediately after such election with a value equal to the portion of the target bonus opportunity that the executive officer elected not to receive in cash, and such award vests based on the achievement of the Company’s pre-defined performance targets. Further, such executive officer may earn up to 200% of the target number of restricted stock units based on actual performance, provided that certain stipulations are met. The Company issued 4,873 time-based restricted stock units and 72,126 performance-based restricted stock units in August 2019. These time-based restricted stock units are subject to the same four-year vesting period as the previously granted units. The performance-based units, issued to key employees, are subject to the Company’s pre-defined targets. These performance-based units will vest over a six month period. Restricted stock unit activity for the nine months ended October 31, 2019 are as follows: Restricted stock units Balance - January 31, 2019 20,164 Granted 526,382 Forfeited (22,185 ) Balance - October 31, 2019 524,361 For the three and nine months ended October 31, 2019, the Company recognized $957 and $1,781 respectively, in restricted stock unit compensation expense, with $3,779 remaining of total unrecognized compensation costs related to these awards as of October 31, 2019.

Stock warrants

Stock warrants	9 Months Ended
	Oct. 31, 2019
Warrant [Member]
Stock warrants	10. Stock warrants As of October 31, 2019 and January 31, 2019, the following warrants to purchase common and preferred stock were outstanding: Number of warrants Warrants to purchase October 31, January 31, Exercise price Expiration Senior A Preferred — 116,232 $ 2.19 October 1, 2021 Senior A Preferred — 672,560 $ 3.00 November 1, 2026 Junior Preferred — 489,605 $ 0.01 September 5, 2020 Redeemable Preferred 358,244 $ 0.01 September 5, 2020 Total preferred stock (liability-classified) — 1,636,641 Common stock — 166,952 $ 2.02 October 21, 2025 Common stock — 89,459 $ 3.49 November 1, 2026 Common stock 75,137 — $ 8.02 February 28, 2029 Common stock (converted from preferred stock) 153,041 — $ 6.59 November 1, 2026 Total common stock (equity-classified) 228,178 256,411 The following table summarizes the activity for the Company’s warrants for the periods presented: Common Preferred Balance - 256,411 1,636,641 Granted 150,274 — Conversion of preferred stock warrants to common stock warrants 581,798 — Exercised (760,305 ) (1,636,641 ) Balance - 228,178 — The following table is a reconciliation of the warrant liability measured at fair value: Warrant Liability Balance at January 31, 2019 $ 5,498 Change in fair value of stock warrants nine months ended October 31, 2019 3,307 Conversion of convertible preferred stock warrants (8,805 ) Balance at October 31, 2019 $ — Upon the closing of the IPO in July 2019, the Company’s outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase an aggregate of 581,798 shares of common stock. Upon the conversion, the Company reclassified the warrants to equity and recorded the then current value of the warrant liability on the date of reclassification to additional paid-in-capital. 153,041 sh a f to purchase c ommon stock In July and September , the existing common stock warrant holders completed the cashless exercise of the warrants, resulting in the issuance of 256,411 and 75,137 shares of common stock , respectively , whereby 25,919 and 22,114 shares of common stock , respectively, were withheld by the Company to pay for the exercise price of the warrants , and 230,492 and 53,023 shares of common stock were issued, respectively.

Fair value measurements

Fair value measurements	9 Months Ended
	Oct. 31, 2019
Fair Value Disclosures [Abstract]
Fair value measurements	11. Fair value measurements The carrying value of the Company’s short-term financial instruments, including accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. The Company uses certain derivative financial instruments as part of its risk management strategy to reduce its foreign currency risk. The Company recognizes all derivatives on the balance sheet at fair value based on quotes obtained from financial institutions. The fair value of its foreign currency contracts as of October 31, 2019 and January 31, 2019 was a liability of $24 and $143, respectively, which are included in Accounts payable on the accompanying balance sheet. The fair value of the foreign currency contracts are considered Level 2 in the fair value hierarchy as of October 31, 2019 and January 31, 2019, respectively. Warrant Liability—The warrant liability is related to the warrants to purchase shares of preferred stock ( S The Company used the Black-Scholes option-pricing model, which incorporated weighted-average inputs and assumptions, to value the warrant liability as of January 31, 2019 and as of the date of conversion. As of January 31, 2019, the warrant liability was valued at $5,498 as a non-current The Black-Scholes M pre-stock January 31, 2019 Series A Junior Redeemable Estimated fair value of preferred stock $ 5.80 $ 4.88 $ 0.01 Exercise price $ 2.88 $ 0.01 $ 0.01 Remaining term (in years) 7.01 1.60 1.60 Risk-free interest rate 2.6 % 2.5 % 2.5 % Expected volatility 45.1 % 45.1 % 45.1 % Dividend yield 0.0 % 0.0 % 0.0 % The Black Scholes Method and following assumptions were used to measure the fair market value of the warrant liability upon the conversion date: Series A Junior Estimated fair value of preferred stock $ 18.00 $ 18.00 Exercise price $ 6.33 $ 0.01 Remaining term (in years) 6.55 1.13 Risk-free interest rate 1.9 % 1.9 % Expected volatility 45.9 % 45.9 % Dividend yield 0.0 % 0.0 % As the Company refinanced all of its debt on February 28, 2019 ( S The Company did not have any transfers of assets and liabilities between levels of the fair value measurement hierarchy during the nine months ended October 31, 2019 and 2018. The Company’s cash and cash equivalents includes money market funds which is measured at fair value. The Company consider these investments within Level 1 of the fair value hierarchy.

Commitments and contingencies

Commitments and contingencies	9 Months Ended
	Oct. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	12. Commitments and contingencies (a) Operating and capital leases The Company leases its office premises in New York, North Carolina, and Ottawa under operating leases which expire on various dates through August 2022. The Company recognizes rent expense under such arrangements on a straight-line basis. Rent expense under such operating leases amounted to $462 and $453 for the three months ended October 31, 2019 and 2018, respectively. Rent expense under such operating leases amounted to $1,373 and $1,350 for the nine months ended October 31, 2019 and 2018, respectively. As of October 31, 2019, the aggregate minimum net rental payments for non-cancelable 2020 (Remaining three months) $ 443 Year ending January 31, 2021 1,824 2022 819 2023 464 Total operating lease payments $ 3,550 During the nine months ended October 31, 2019 and in prior years, the Company entered into several capital leases for equipment and software. The leases are for 30-36 2020 (Remaining three months) $ 611 Year ending January 31, 2021 2,404 2022 1,621 2023 200 Total capital lease payments $ 4,836 Less amounts representing interest (452 ) Total capital lease payments, net of interest 4,384 Less current portion (2,413 ) Total capital lease payments, net of interest and current portio n $ 1,971 Interest expense related to capital leases was $64 and $78 for the three months ended October 31, 2019 and 2018, respectively. Interest expense related to capital leases was $215 and $190 for the nine months ended October 31, 2019 and 2018, respectively. (b) Legal proceedings In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes or claims. Although the Company cannot predict with assurance the outcome of any litigation, the Company does not believe there are currently any such actions that, if resolved unfavorably, would have a material impact on its financial condition, results of operations or cash flows.

Income taxes

Income taxes	9 Months Ended
	Oct. 31, 2019
Income Tax Disclosure [Abstract]
Income taxes	13. Income taxes The effective tax rate is 0% and 0% in the nine months ended October 31, 2019 and 2018, respectively. The difference between the U.S. Statutory rate of 21% and the effective tax rate is primarily due to the change in valuation allowance. The Company has recorded a full valuation allowance against its deferred tax assets at October 31, 2019 and January 31, 2019.

Net loss per share attributable

Net loss per share attributable to common stockholders	9 Months Ended
	Oct. 31, 2019
Earnings Per Share [Abstract]
Net loss per share attributable to common stockholders	14. Net loss per share attributable to common stockholders Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three months ended October 31, Nine months ended October 31, 2019 2018 2019 2018 Numerator: Net loss $ (2,437 ) $ (4,172 ) $ (16,625 ) $ (9,983 ) Preferred stock dividend paid — — (14,955 ) — Accretion of redeemable convertible preferred stock to redemption value — (9,236 ) (56,175 ) (20,962 ) Net loss attributable to common stockholders $ (2,437 ) $ (13,408 ) $ (87,755 ) $ (30,945 ) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 35,790,951 1,909,858 15,007,247 1,176,833 Net loss attributable to common stockholders $ (0.07 ) $ (7.02 ) $ (5.85 ) $ (26.30 ) The Company’s potential dilutive securities, which include Convertible Preferred, stock options, restricted stock units and outstanding warrants to purchase shares of common and preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: October 31, 2019 October 31, Redeemable convertible preferred stock (as-converted — 25,311,535 Stock options to purchase common stock and restricted stock units 6,645,106 5,094,108 Warrants to purchase convertible preferred stock — 581,798 Warrants to purchase common stock 228,178 256,411 6,873,284 31,243,853

Related party transactions

Related party transactions	9 Months Ended
	Oct. 31, 2019
Related Party Transactions [Abstract]
Related party transactions	15. Related party transactions The Company recognized revenue totaling approximately $1,223 and $1,115 from an affiliate of a stockholder of the Company for the three months ended October 31, 2019 and 2018, respectively. The Company recognized revenue totaling approximately $4,098 and $3,693 from an affiliate of a stockholder of the Company for the nine months ended October 31, 2019 and 2018, respectively. Accounts receivable from the affiliate totaled approximately $1,277 and $598 as of October 31, 2019 and January 31, 2019, respectively.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	9 Months Ended
	Oct. 31, 2019
Accounting Policies [Abstract]
Basis of presentation	(a) Basis of presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) and include the accounts of Phreesia, Inc. and its branch operation in Canada.
Fiscal Period	(b) Fiscal year The Company’s fiscal year ends on January 31. References to fiscal 2018 and 2019 refer to the fiscal year ended January 31, 2018 and 2019, respectively.
Use of estimates	(a) Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments. Although management believes its estimates and assumptions are reasonable under the circumstances at the time they are made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Actual results may differ from those estimates made under different assumptions or circumstances. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use
Concentrations of credit risk	(b) Concentrations of credit risk Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one or two business days to settle which mitigates the associated risk of concentration. The Company has one third-party payment processor. The Company’s customers are primarily physician’s offices located in the United States and pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the three and nine months ended October 31, 2019 and 2018.
New accounting pronouncements	(c) New accounting pronouncements Recent accounting pronouncements not yet adopted In August 2018, the FASB issued ASU No. 2018-13, : Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-13). 2018-13 In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, internal-use In February 2016, the FASB issued ASU 2016-02, Leases right-of-use 20 use-of-hindsight

Composition of certain financ_2

Composition of certain financial statement captions (Tables)	9 Months Ended
	Oct. 31, 2019
Composition Of Certain Financial Statement [Abstract]
Schedule of accrued liabilities	Accrued expenses as of October 31, 2019 and January 31, 2019 are as follows: October 31, January 31, 2019 2019 Payment processing fees liability $ 2,428 $ 2,267 Commission and bonus 2,653 320 Accrued payment related to acquisition of Vital Score 350 350 Vacation 543 417 Other 2,044 1,744 Total $ 8,018 $ 5,098
Schedule of property and equipment	Property and equipment as of October 31, 2019 and January 31, 2019 are as follows: Useful Life (years) 31 2019 2019 PhreesiaPads and Arrivals Stations 3 $ 26,470 $ 22,747 Computer equipment 3 17,093 14,338 Computer software 3 2,223 2,166 Hardware development 3 1,024 1,024 Furniture and fixtures 7 683 647 Leasehold improvements 2 1,175 1,151 Total property and equipment $ 48,668 $ 42,073 Less accumulated depreciation and amortization (34,304 ) (27,862 ) Property and equipment — net $ 14,364 $ 14,211
Schedule of intangible assets	The following presents the details of intangible assets as of October 31, 2019 and January 31, 2019. Useful Life (years) October 31, January 31, 2019 Acquired technology gross carrying value 5 $ 490 $ 490 Customer relationship gross carrying value 7 980 980 Total intangible assets $ 1,470 $ 1,470 Less accumulated amortization (212 ) (33 ) Net carrying value $ 1,258 $ 1,437
Schedule of estimated amortization expense for intangible assets	The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of October 31, 2019: 2020 (Remaining three months) $ 60 Years ending January 31, 2021 238 2022 238 2023 238 2024 224 2025 - thereafter 260 Total $ 1,258
Schedule of accounts receivable	Accounts receivable as of October 31, 2019 and January 31, 2019 are as follows: October 31, January 31, 2019 2019 Billed $ 19,759 $ 15,990 Unbilled 978 636 Total accounts receivable, gross $ 20,737 $ 16,626 Less allowance for doubtful accounts (729 ) (517 ) Total accounts receivable $ 20,008 $ 16,109

Revenues (Tables)

Revenues (Tables)	9 Months Ended
	Oct. 31, 2019
Revenue from Contract with Customer [Abstract]
Rollforward of contract assets and contract liabilities	The following table represents a rollforward of contract assets and contract liabilities: Contract assets Contract January 31, 2019 $ 636 $ 6,488 Amount transferred to receivables from contract assets (576 ) — Contract asset additions 918 — Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (11,168 ) Increases due to invoicing prior to satisfaction or performance obligations — 10,006 October 31, 2019 $ 978 $ 5,326
Deferred contract acquisition costs	The following table represents a rollforward of deferred contract acquisition costs: 2019 2019 Beginning balance $ 3,194 $ 2,334 Additions to deferred contract acquisition costs 1,414 2,500 Amortization of deferred contract acquisition costs (1,465 ) (1,640 ) Ending balance 3,143 3,194 Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,631 1,673 Deferred contract acquisition costs, non current 1,512 1,521 Total deferred contract acquisition costs $ 3,143 $ 3,194

Debt (Tables)

Debt (Tables)	9 Months Ended
	Oct. 31, 2019
Debt Disclosure [Abstract]
Schedule of long-term debt instruments	As of October 31, 2019 and January 31, 2019, the Company had the following outstanding loan balances: October 31, January 31, Term loan $ 20,000 $ 1,042 Line of credit — 7,800 Loan payable — 20,000 Total debt $ 20,000 $ 28,842 Less current maturities — (97 ) Less deferred financing costs (983 ) (996 ) Plus accrued interest 121 — Plus accrued final payment 217 169 Long term debt, net of current portion $ 19,355 $ 27,918
Schedule of maturities of long-term debt	As of October 31, 2019, the Company’s long-term debt is payable as follows: 2020 (Remaining three months) $ — Year ending January 31, 2021 — 2022 6,111 2023 6,667 2024 6,667 2025 - thereafter 555 Total long-term debt payment s $ 20,000

Equity-based compensation (Tabl

Equity-based compensation (Tables)	9 Months Ended
	Oct. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of stock option activity	Stock option activity for the nine months ended October 31, 2019 are as follows: Number of Weighted- Weighted- Aggregate (in thousands) Outstanding 5,055,505 $ 2.45 Granted in nine months ended October 31, 2019 1,230,382 $ 8.78 Exercised (111,515 ) $ 3.98 Forfeited and expired (53,627 ) $ 3.38 Outstanding and expected to vest 6,120,745 $ 3.67 6.35 $ 140,339 Exercisable 4,197,481 $ 2.09 4.84 $ 103,178 Amount vested in nine months ended October 31, 2019 621,206 $ 4.03
Schedule of restricted stock units	Restricted stock unit activity for the nine months ended October 31, 2019 are as follows: Restricted stock units Balance - January 31, 2019 20,164 Granted 526,382 Forfeited (22,185 ) Balance - October 31, 2019 524,361
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of weighted average assumptions	The weighted average assumptions are provided below. For the three months ended For the nine months ended October 31, October 31, October 31, October 31, 2019 2018 2019 2018 Risk-free interest rate 1.81 % 2.90 % 2.18 % 2.83 % Expected dividends None None None None Expected term (in years) 6.25 6.25 6.25 6.25 Volatility 45.90 % 45.00 % 45.15 % 45.00 % Weighted average fair market value of grants $ 12.42 $ 3.99 $ 4.99 $ 3.72

Stock warrants (Tables)

Stock warrants (Tables)	9 Months Ended
	Oct. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Schedule of warrants to purchase common and preferred stock outstanding	As of October 31, 2019 and January 31, 2019, the following warrants to purchase common and preferred stock were outstanding: Number of warrants Warrants to purchase October 31, January 31, Exercise price Expiration Senior A Preferred — 116,232 $ 2.19 October 1, 2021 Senior A Preferred — 672,560 $ 3.00 November 1, 2026 Junior Preferred — 489,605 $ 0.01 September 5, 2020 Redeemable Preferred 358,244 $ 0.01 September 5, 2020 Total preferred stock (liability-classified) — 1,636,641 Common stock — 166,952 $ 2.02 October 21, 2025 Common stock — 89,459 $ 3.49 November 1, 2026 Common stock 75,137 — $ 8.02 February 28, 2029 Common stock (converted from preferred stock) 153,041 — $ 6.59 November 1, 2026 Total common stock (equity-classified) 228,178 256,411
Schedule of summarizes the activity for the company's warrants	The following table summarizes the activity for the Company’s warrants for the periods presented: Common Preferred Balance—January 31, 2019 256,411 1,636,641 Granted 150,274 — Conversion of preferred stock warrants to common stock warrants 581,798 — Exercised (760,305 ) (1,636,641 ) Balance—October 31, 2019 228,178 —
Schedule of reconciliation of the warrant liability measured at fair value	The following table is a reconciliation of the warrant liability measured at fair value: Warrant Liability Balance at January 31, 2019 $ 5,498 Change in fair value of stock warrants nine months ended October 31, 2019 3,307 Conversion of convertible preferred stock warrants (8,805 ) Balance at October 31, 2019 $ —

Fair value measurements (Tables

Fair value measurements (Tables)	9 Months Ended
	Oct. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of weighted-average inputs and assumptions	The Black-Scholes method and the following weighted-average inputs and assumptions was utilized to determine the fair value of the warrants as of January 31, 2019, pre-stock January 31, 2019 Series A Junior Redeemable Estimated fair value of preferred stock $ 5.80 $ 4.88 $ 0.01 Exercise price $ 2.88 $ 0.01 $ 0.01 Remaining term (in years) 7.01 1.60 1.60 Risk-free interest rate 2.6 % 2.5 % 2.5 % Expected volatility 45.1 % 45.1 % 45.1 % Dividend yield 0.0 % 0.0 % 0.0 %
Schedule of measure the fair market value of the warrant liability	The Black Scholes Method and following assumptions were used to measure the fair market value of the warrant liability upon the conversion date: Series A Junior Estimated fair value of preferred stock $ 18.00 $ 18.00 Exercise price $ 6.33 $ 0.01 Remaining term (in years) 6.55 1.13 Risk-free interest rate 1.9 % 1.9 % Expected volatility 45.9 % 45.9 % Dividend yield 0.0 % 0.0 %

Commitments and contingencies (

Commitments and contingencies (Tables)	9 Months Ended
	Oct. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of aggregate minimum net rental payments	As of October 31, 2019, the aggregate minimum net rental payments for non-cancelable 2020 (Remaining three months) $ 443 Year ending January 31, 2021 1,824 2022 819 2023 464 Total operating lease payments $ 3,550
Schedule of minimum lease payments	During the nine months ended October 31, 2019 and in prior years, the Company entered into several capital leases for equipment and software. The leases are for 30-36 2020 (Remaining three months) $ 611 Year ending January 31, 2021 2,404 2022 1,621 2023 200 Total capital lease payments $ 4,836 Less amounts representing interest (452 ) Total capital lease payments, net of interest 4,384 Less current portion (2,413 ) Total capital lease payments, net of interest and current portio n $ 1,971

Net loss per share attributab_2

Net loss per share attributable to common stockholders (Tables)	9 Months Ended
	Oct. 31, 2019
Earnings Per Share [Abstract]
Schedule of earnings per share, basic and diluted	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three months ended October 31, Nine months ended October 31, 2019 2018 2019 2018 Numerator: Net loss $ (2,437 ) $ (4,172 ) $ (16,625 ) $ (9,983 ) Preferred stock dividend paid — — (14,955 ) — Accretion of redeemable convertible preferred stock to redemption value — (9,236 ) (56,175 ) (20,962 ) Net loss attributable to common stockholders $ (2,437 ) $ (13,408 ) $ (87,755 ) $ (30,945 ) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 35,790,951 1,909,858 15,007,247 1,176,833 Net loss attributable to common stockholders $ (0.07 ) $ (7.02 ) $ (5.85 ) $ (26.30 )
Schedule of shares excluded from computation of diluted net loss per share	The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: October 31, 2019 October 31, Redeemable convertible preferred stock (as-converted — 25,311,535 Stock options to purchase common stock and restricted stock units 6,645,106 5,094,108 Warrants to purchase convertible preferred stock — 581,798 Warrants to purchase common stock 228,178 256,411 6,873,284 31,243,853

Background and liquidity - Addi

Background and liquidity - Additional Information (Detail) $ / shares in Units, $ in Thousands	Jul. 22, 2019USD ($)$ / sharesshares	Jul. 03, 2019	Oct. 31, 2019USD ($)	Oct. 31, 2018USD ($)	Oct. 31, 2019USD ($)	Oct. 31, 2018USD ($)
Background And Liquidity [Line Items]
Proceeds from issuance initial public offering					$ 130,781	$ 0
Deferred offering costs					5,944	0
Payments of preferred stock dividends			$ 0	$ 0	$ 14,955	$ 0
Stockholder equity reverse stock splits		0.4551-for-1
Reverse stock splits shares combined		2.1973
Year formed					2005
Minimum [Member]
Background And Liquidity [Line Items]
Number of months the company have sufficient to fund its operations					12 months
IPO [Member]
Background And Liquidity [Line Items]
Stock issued during period initial public offering | shares	7,812,500
Share price | $ / shares	$ 18
Proceeds from issuance initial public offering	$ 130,781
Underwriting discounts and commission	9,844
Deferred offering costs	$ 6,084
Conversion and exercise of preferred stock warrants | shares	588,763
Payments of preferred stock dividends	$ 14,955				$ 14,955
IPO [Member] | Stockholders [Member]
Background And Liquidity [Line Items]
Stock issued during period initial public offering | shares	2,868,923

Composition of certain financ_3

Composition of certain financial statement captions - Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019
Accrued Expenses [Abstract]
Payment processing fees liability	$ 2,428	$ 2,267
Commission and bonus	2,653	320
Accrued payment related to acquisition of Vital Score	350	350
Vacation	543	417
Other	2,044	1,744
Total	$ 8,018	$ 5,098

Composition of certain financ_4

Composition of certain financial statement captions - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	9 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 48,668	$ 42,073
Less accumulated depreciation and amortization	(34,304)	(27,862)
Property and equipment — net	14,364	14,211
PhreesiaPads and Arrivals Stations [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 26,470	22,747
Property and equipment Useful Life	3 years
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 17,093	14,338
Property and equipment Useful Life	3 years
Computer software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 2,223	2,166
Property and equipment Useful Life	3 years
Hardware development [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 1,024	1,024
Property and equipment Useful Life	3 years
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 683	647
Property and equipment Useful Life	7 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment Gross	$ 1,175	$ 1,151
Property and equipment Useful Life	2 years

Composition of certain financ_5

Composition of certain financial statement captions - Schedule Of Finite Lived Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended
	Oct. 31, 2019	Jan. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 1,470	$ 1,470
Less accumulated amortization	(212)	(33)
Net carrying value	1,258	1,437
Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 490	490
Finite-lived intangible asset, useful life	5 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 980	$ 980
Finite-lived intangible asset, useful life	7 years

Composition of certain financ_6

Composition of certain financial statement captions - Schedule of Finite Lived Intangible Assets Future Amortization Expense (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
2020 (Remaining three months)	$ 60
2021	238
2022	238
2023	238
2024	224
2025 - thereafter	260
Net carrying value	$ 1,258	$ 1,437

Composition of certain financ_7

Composition of certain financial statement captions - Schedule Of Accounts Notes Loans And Financing Receivable (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019
Accounts Receivable Additional Disclosures [Abstract]
Billed	$ 19,759	$ 15,990
Unbilled	978	636
Total accounts receivable, gross	20,737	16,626
Less allowance for doubtful accounts	(729)	(517)
Total accounts receivable	$ 20,008	$ 16,109

Composition of certain financ_8

Composition of certain financial statement captions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Jan. 31, 2019	Oct. 31, 2018	Jul. 31, 2019	Jul. 22, 2019
Composition Of Certain Financial Statement [Line Items]
Depreciation	$ 2,153	$ 1,966	$ 6,444		$ 5,515
Capitalized computer software net	8,501		8,501	$ 7,816
Amortization of intangible assets	59	0	178		0
Deferred offering costs						$ 6,084	$ 6,084
Accumulated amortization of capital lease assets	7,127		7,127	5,369
Capital Leased Assets, Gross	11,973		11,973	10,235
Additional deferred offering costs	56
Phreesia Platform Software [Member]
Composition Of Certain Financial Statement [Line Items]
Capitalized cost of computer software	1,452	1,274	4,329		3,744
Capitalized computed software amortization	1,266	$ 1,037	3,645		$ 2,912
Capitalized computer software net	8,501		$ 8,501	$ 7,816
Acquired Technology [Member]
Composition Of Certain Financial Statement [Line Items]
Remaining useful life of acquired intangible assets			4 years 1 month 6 days	4 years 9 months 18 days
Customer Relationships [Member]
Composition Of Certain Financial Statement [Line Items]
Remaining useful life of finite lived intangible assets			6 years 1 month 6 days	6 years 9 months 18 days
Depreciation [Member]
Composition Of Certain Financial Statement [Line Items]
Capital leases depreciation			$ 1,758
Other Assets [Member]
Composition Of Certain Financial Statement [Line Items]
Deferred offering costs	$ 0		$ 0	$ 540

Revenues - Schedule Of Rollforw

Revenues - Schedule Of Rollforward of contract assets and contract liabilities (Detail) $ in Thousands	9 Months Ended
	Oct. 31, 2019USD ($)
Revenue from Contract with Customer [Abstract]
Beginning balance - Contract assets (unbilled accounts receivable)	$ 636
Amount transferred to receivables from contract assets	(576)
Contract asset additions	918
Ending balance - Contract assets (unbilled accounts receivable)	978
Beginning balance - Contract liabilities (deferred revenue)	6,488
Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period	(11,168)
Increases due to invoicing prior to satisfaction or performance obligations	10,006
Ending balance - Contract liabilities (deferred revenue)	$ 5,326

Revenues - Schedule Of Deferred

Revenues - Schedule Of Deferred contract acquisition costs (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019	Oct. 31, 2019	Jan. 31, 2019
Revenue from Contract with Customer [Abstract]
Beginning balance	$ 3,194	$ 2,334	$ 2,334
Additions to deferred contract acquisition costs	1,414		2,500
Amortization of deferred contract acquisition costs	(1,465)	(1,179)	(1,640)
Ending balance	3,143		3,194
Deferred contract acquisition costs, current (to be amortized in next 12 months)				$ 1,631	$ 1,673
Deferred contract acquisition costs, non current				1,512	1,521
Total deferred contract acquisition costs	$ 3,143	$ 2,334	$ 2,334	$ 3,143	$ 3,194

Revenues - Additional Informati

Revenues - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019
Revenue From Contract With Customer [Line Items]
Revenue from Contract with Customer	$ 32,843	$ 24,756	$ 91,968	$ 73,406
Capitalized contract cost, amortization			1,465	1,179	$ 1,640
Selling and Marketing Expense [Member]
Revenue From Contract With Customer [Line Items]
Capitalized contract cost, amortization	491	416	1,465	1,179
Subscription And Related Services [Member]
Revenue From Contract With Customer [Line Items]
Revenue from Contract with Customer	14,606	10,929	41,292	31,391
Subscription And Related Services [Member] | Onsite kiosks [Member]
Revenue From Contract With Customer [Line Items]
Revenue from Contract with Customer	$ 1,496	$ 1,197	$ 4,462	$ 3,388

Debt - Schedule Of Outstanding

Debt - Schedule Of Outstanding loan balances (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019	Nov. 07, 2016
Debt Instrument [Line Items]
Long term debt gross	$ 20,000	$ 28,842
Less current maturities	0	(97)
Less deferred financing costs	(983)	(996)
Plus accrued interest	121	0
Plus accrued final payment	217	169
Long term debt, net of current portion	19,355	27,918
Term Loan [Member]
Debt Instrument [Line Items]
Long term debt gross	20,000	1,042
Line of Credit [Member]
Debt Instrument [Line Items]
Long term debt gross	0	7,800
Loans Payable [Member]
Debt Instrument [Line Items]
Long term debt gross	$ 0	$ 20,000	$ 20,000

Debt - Schedule of long-term de

Debt - Schedule of long-term debt maturities (Detail) $ in Thousands	Oct. 31, 2019USD ($)
Debt Disclosure [Abstract]
2020 (Remaining three months)	$ 0
2021	0
2022	6,111
2023	6,667
2024	6,667
2025 - thereafter	555
Total long-term debt payments	$ 20,000

Debt - Additional information (

Debt - Additional information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jul. 22, 2019	Feb. 28, 2019	Jan. 31, 2019	May 31, 2017	Nov. 07, 2016	Feb. 28, 2019	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018
Debt [Line Items]
Final fee charged to interest			$ 169				$ 217		$ 217
Repayments of revolving credit	$ 17,676								17,676	$ 3,500
Long term debt gross			28,842				$ 20,000		$ 20,000
Number of securities called by warrants							428,757		428,757
Write-off of deferred financing costs									$ 773
Extinguishment and modification fee									1,073	0
Debt issuance costs									$ 112	0
Debt instrument fee percentage									5
Prepayment fee							$ 300		$ 300
Amended and Restated Loan and Security Agreement [Member]
Debt [Line Items]
Number of securities called by warrants		150,274				150,274
Exercise price		$ 8.02				$ 8.02
Prepayment fee percentage		3.00%				3.00%
Prepayment fee percentage		2.00%				2.00%
Prepayment fee percentage		1.00%				1.00%
Warrants fair value disclosure		$ 833				$ 833
Warrants expiration period		2029-02
Loans Payable [Member]
Debt [Line Items]
Maximum borrowing capacity					$ 10,000
Interest expense							0	$ 498	168	1,663
Amortization of financing costs							0	$ 30	0	$ 89
Effective interest rate percentage								12.50%		12.50%
Expiration period					5 years
Proceeds from lines of credit				$ 10,000
Stated interest percentage					11.00%
Loan agreement, term					principal due in 30 equal installments beginning in June 2019.
Long term debt gross			20,000		$ 20,000		0		0
Term Loan [Member]
Debt [Line Items]
Maximum borrowing capacity			$ 3,500
Interest rate description						Prime Rate as quoted by Wall Street Journal print edition less three-quarters of one percent (0.75%)
Final fee charged to interest							0	$ 7	6	$ 21
Interest expense							0	23	16	73
Amortization of financing costs							0	$ 6	$ 5	$ 18
Effective interest rate percentage								5.10%		5.10%
Description of variable rate basis			Prime Rate was 5.50%
Expiration period									36 months
Long term debt gross			$ 1,042				20,000		$ 20,000
Prepayment fee							175		175
Term Loan [Member] | Amended and Restated Loan and Security Agreement [Member]
Debt [Line Items]
Final fee charged to interest		$ 217				$ 217
Interest expense							386		1,046
Amortization of financing costs							$ 38		$ 103
Effective interest rate percentage							3.90%		3.90%
Description of variable rate basis		prime rate plus 1.50%
Loan agreement, term		Principal payments due under the term loans are due in 36 equal monthly installments beginning in March 2021.
Long term debt gross		$ 20,000	$ 1,042			20,000
Description of variable rate basis		prime plus 0.75%
Unused capacity fee percentage		0.15%
Termination fee percentage		1.50%
Debt instrument fee percentage		2.75%
Term Loan B Advance [Member] | Amended and Restated Loan and Security Agreement [Member]
Debt [Line Items]
Maximum borrowing capacity		$ 10,000				10,000
Term Loan C Advance [Member] | Amended and Restated Loan and Security Agreement [Member]
Debt [Line Items]
Maximum borrowing capacity		15,000				15,000
Revolving Credit Facility [Member]
Debt [Line Items]
Interest expense							$ 0	$ 42	$ 166	$ 115
Amortization of financing costs							0	$ 18	$ 13	53
Description of variable rate basis									prime rate plus 1.00%
Maturity date									Nov. 30, 2019
Weighted-average borrowings outstanding									$ 979	$ 971
Revolving line of credit					$ 10,000		20,000		$ 20,000
Revolving Credit Facility [Member] | Amended and Restated Loan and Security Agreement [Member]
Debt [Line Items]
Maximum borrowing capacity		25,000				25,000
Interest rate description									Borrowings under the revolving credit facility bear interest, which is payable monthly, at a floating rate equal to the greater of the bank’s prime rate less 0.50%, or 5.0% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the greater of prime less 0.75%, or 4.75%.
Interest expense							32		$ 342
Amortization of financing costs									$ 84
Maturity date									Feb. 28, 2024
Expiration period									5 years
Borrowing capacity decription									Borrowings under the revolving credit facility are subject to a borrowing base equal to 80% of eligible accounts receivable plus a percentage of recurring revenue, as defined, not to exceed $25,000 in the aggregate.
Annual fee per year during the first three years									$ 100
Annual fee per year in years four and five									75
Revolving line of credit		$ 25,000				$ 25,000	$ 25,000		$ 25,000

Common Stock - Additional infor

Common Stock - Additional information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jul. 22, 2019	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019
Class of Stock [Line Items]
Common stock authorized		500,000,000		80,000,000
Common stock par value		$ 0.01		$ 0.01
Proceeds from proceeds from issuance intial public offering		$ 130,781	$ 0
IPO [Member]
Class of Stock [Line Items]
Common stock authorized	500,000,000
Common stock par value	$ 0.01
Stock issued during period initial public offering	7,812,500
Share price	$ 18
Proceeds from proceeds from issuance intial public offering	$ 130,781
Convertible preferred stock converted	588,763
Cashless exercise of common stock warrants		53,023
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock converted	25,311,515

Preferred stock - Additional in

Preferred stock - Additional information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jul. 22, 2019	Oct. 31, 2019	Jul. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Apr. 30, 2019	Jan. 31, 2019	Jul. 31, 2018	Apr. 30, 2018	Jan. 31, 2018
Preferred Stock [Line Items]
Aggregate of common stock		35,872,057			35,872,057			1,994,721
Preferred stock authorized	20,000,000
Preferred stock par value	$ 0.01
Dividend paid		$ 0		$ 0	$ 14,955	$ 0
IPO [Member]
Preferred Stock [Line Items]
Aggregate of common stock	25,311,515
Dividend paid	$ 14,955				$ 14,955
Junior Convertible Preferred Stock [Member]
Preferred Stock [Line Items]
Temporary equity cancelled			(32,746,041)
Temporary equity, shares outstanding		0	0	32,746,041	0	32,746,041	32,746,041	32,746,041	32,746,041	32,746,041	32,746,041
Temporary equity, shares issued		0			0			32,746,041
Redeemable Preferred Stock [Member]
Preferred Stock [Line Items]
Temporary equity cancelled	42,560,530		(42,560,530)
Temporary equity, shares outstanding		0	0	42,560,782	0	42,560,782	42,560,530	42,560,530	42,560,782	42,560,530	42,560,530
Temporary equity, shares issued		0			0			42,560,530

Equity-based compensation - Wei

Equity-based compensation - Weighted Average Assumptions (Detail) - Stock Option [Member] - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.81%	2.90%	2.18%	2.83%
Expected dividends	$ 0	$ 0	$ 0	$ 0
Expected term (in years)	6 years 3 months	0 years	6 years 3 months	6 years 3 months
Volatility	45.90%	45.00%	45.15%	45.00%
Weighted average fair market value of grants	$ 12.42	$ 3.99	$ 4.99	$ 3.72

Equity-based compensation - Sto

Equity-based compensation - Stock Option Activity (Detail) - Stock Option [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Oct. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	5,055,505
Granted	1,230,382
Exercised	(111,515)
Forfeited and expired	(53,627)
Number of options outstanding and expected to vest	6,120,745
Exercisable	4,197,481
Amount vested at the end of the period	621,206
Weighted- average exercise price outstanding	$ 2.45
Granted	8.78
Exercised	3.98
Forfeited and expired	3.38
Weighted- average exercise price outstanding and expected to vest	3.67
Exercisable	2.09
Amount vested at the end of the period	$ 4.03
Weighted- average remaining contractual life outstanding and expected to vest	6 years 4 months 6 days
Weighted- average remaining contractual life exercisable	4 years 10 months 2 days
Aggregate intrinsic value outstanding and expected to vest	$ 140,339
Aggregate intrinsic value exercisable	$ 103,178

Equity-based compensation - Add

Equity-based compensation - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 20, 2019	Mar. 25, 2019	Oct. 14, 2014	Aug. 31, 2019	Jun. 30, 2019	Jan. 31, 2019	Jan. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value										$ 1,728	$ 1,658
Weighted average Term										2 years 11 months 23 days
Option plan expense								$ 809	$ 447	$ 2,051	$ 950
Unrecognized compensation cost to stock option								6,975		6,975
Incremental expense								173		$ 173
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date		2026-03
RSU's granted		390,794								526,382
Restricted stock expense								957		$ 1,781
Unrecognised compensation costs								$ 3,779		$ 3,779
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option		10.00%
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option		20.00%
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option		30.00%
Restricted Stock Units (RSUs) [Member] | Share-based Payment Arrangement, Year 4 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option		40.00%
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's granted				72,126
Time Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's granted				4,873
Maximum [Member] | Restricted Stock Units (RSUs) [Member] | Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option				200.00%
Director [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date						2026-06
RSU's granted	58,589
2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options issued										151,548
Expiration date			2017-08
Number of shares available for issuance			4,424,986
2018 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized							3,048,490
2019 Stock Option And Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance					2,139,683			2,129,560		2,129,560
Percentage increase in number of shares reserved					5.00%
Percentage of vest option					25.00%
2019 Stock Option And Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
vesting term					4 years
2019 Stock Option And Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
vesting term					10 years
2019 Employee Stock Purchse Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance					855,873			855,873		855,873

Equity-based compensation - Res

Equity-based compensation - Restricted stock Units (Detail) - Restricted Stock Units (RSUs) [Member] - shares	Mar. 25, 2019	Oct. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance		20,164
Granted	390,794	526,382
Forfeited		(22,185)
Ending balance		524,361

Stock warrants - warrants to pu

Stock warrants - warrants to purchase common and preferred stock (Detail) - $ / shares	Oct. 31, 2019	Jan. 31, 2019
Preferred stock
Class of Warrant or Right [Line Items]
Number of warrants	0	1,636,641
Senior A Preferred | Exercise price 2.19, Expiration October 1, 2021
Class of Warrant or Right [Line Items]
Number of warrants	0	116,232
Exercise price		$ 2.19
Exercise price Expiration		Oct. 1, 2021
Senior A Preferred | Exercise price 3.00, Expiration November 1, 2026
Class of Warrant or Right [Line Items]
Number of warrants	0	672,560
Exercise price		$ 3
Exercise price Expiration		Nov. 1, 2026
Junior Preferred | Exercise price 0.01, Expiration September 5, 2020
Class of Warrant or Right [Line Items]
Number of warrants	0	489,605
Exercise price		$ 0.01
Exercise price Expiration		Sep. 5, 2020
Redeemable Preferred | Exercise price 0.01, Expiration September 5, 2020
Class of Warrant or Right [Line Items]
Number of warrants	0	358,244
Exercise price		$ 0.01
Exercise price Expiration		Sep. 5, 2020
Common stock
Class of Warrant or Right [Line Items]
Number of warrants	228,178	256,411
Common stock | Exercise price 2.02, Expiration October 21, 2025
Class of Warrant or Right [Line Items]
Number of warrants	0	166,952
Exercise price		$ 2.02
Exercise price Expiration		Oct. 21, 2025
Common stock | Exercise price 3.49, Expiration November 1, 2026
Class of Warrant or Right [Line Items]
Number of warrants	0	89,459
Exercise price		$ 3.49
Exercise price Expiration		Nov. 1, 2026
Common stock | Exercise price 8.02, Expiration February 28, 2029
Class of Warrant or Right [Line Items]
Number of warrants	75,137	0
Exercise price	$ 8.02
Exercise price Expiration	Feb. 28, 2029
Common stock (converted from preferred stock) | Exercise price 6.59, Expiration November 1, 2026
Class of Warrant or Right [Line Items]
Number of warrants	153,041	0
Exercise price	$ 6.59
Exercise price Expiration	Nov. 1, 2026

Stock warrants - Activity for t

Stock warrants - Activity for the Company's warrants (Detail)	9 Months Ended
	Oct. 31, 2019shares
Common Stock [Member]
Class of Warrant or Right [Line Items]
Beginning, balance	256,411
Granted	150,274
Conversion of preferred stock warrants to common stock warrants	581,798
Exercised	(760,305)
Ending, balance	228,178
Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Beginning, balance	1,636,641
Exercised	(1,636,641)
Ending, balance	0

Stock warrants - Reconciliation

Stock warrants - Reconciliation of warrant liability (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Beginning, balance			$ 5,498
Change in fair value of stock warrants nine months ended October 31, 2019	$ 0	$ 611	3,307	$ 1,496
Conversion of convertible preferred stock warrants			(8,805)
Ending, balance	$ 0		$ 0

Stock warrants - Additional inf

Stock warrants - Additional information (Detail) - USD ($)	1 Months Ended		9 Months Ended
	Sep. 30, 2019	Jul. 31, 2019	Oct. 31, 2019	Jan. 31, 2019
Class of Warrant or Right [Line Items]
Common stock issued upon the exercise of warrants	75,137	256,411
Common stock withheld	22,114	25,919
Common stock warrants outstanding			$ 0	$ 5,498,000
Securities called by warrants			428,757
Shares Issued Upon Exercise of warrants	53,023	230,492
Convertible Common Stock Warrants [Member]
Class of Warrant or Right [Line Items]
Common stock warrants outstanding		$ 153,041
Common Stock [Member]
Class of Warrant or Right [Line Items]
Common stock warrants outstanding		$ 228,178
Conversion of preferred stock warrants to common stock warrants			581,798
Warrant [Member]
Class of Warrant or Right [Line Items]
Common stock issued upon the exercise of warrants		428,757
Common stock withheld		70,485

Fair value measurements - Sched

Fair value measurements - Schedule Of weighted-average to determine the fair value of warrants (Detail) - Black Scholes Model [Member] - $ / shares	1 Months Ended	9 Months Ended
	Jan. 31, 2019	Oct. 31, 2019
Redeemable Series A Preferred Stock [Member] | Fair Value Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated fair value of preferred stock	$ 5.80
Exercise price	$ 2.88
Remaining term	7 years 3 days
Risk-free interest rate	2.60%
Expected volatility	45.10%
Dividend yield	0.00%
Redeemable Series A Preferred Stock [Member] | Fair Value Warrant Liability Member [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated fair value of preferred stock		$ 18
Exercise price		$ 6.33
Remaining term		6 years 6 months 18 days
Risk-free interest rate		1.90%
Expected volatility		45.90%
Dividend yield		0.00%
Junior Preferred Stock [Member] | Fair Value Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated fair value of preferred stock	$ 4.88
Exercise price	$ 0.01
Remaining term	1 year 7 months 6 days
Risk-free interest rate	2.50%
Expected volatility	45.10%
Dividend yield	0.00%
Junior Preferred Stock [Member] | Fair Value Warrant Liability Member [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated fair value of preferred stock		$ 18
Exercise price		$ 0.01
Remaining term		1 year 1 month 17 days
Risk-free interest rate		1.90%
Expected volatility		45.90%
Dividend yield		0.00%
Redeemable Preferred Stock [Member] | Fair Value Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Estimated fair value of preferred stock	$ 0.01
Exercise price	$ 0.01
Remaining term	1 year 7 months 6 days
Risk-free interest rate	2.50%
Expected volatility	45.10%
Dividend yield	0.00%

Fair value measurements - Addit

Fair value measurements - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019	Oct. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 0	$ 5,498
Fair value, assets, level 1 to level 2 transfers, amount	0		$ 0
Fair value, assets, level 2 to level 1 transfers, amount	0		0
Fair value, liabilities, level 1 to level 2 transfers, amount	0		0
Fair value, liabilities, level 2 to level 1 transfers, amount	0		$ 0
Accounts Payable [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of foreign currency contracts	$ 24	$ 143

Commitments and contingencies -

Commitments and contingencies - Schedule of aggregate minimum net rental payments (Detail) $ in Thousands	Oct. 31, 2019USD ($)
Commitments And Contingencies [Line Items]
2020 (Remaining three months)	$ 443
Year ending January 31, 2021	1,824
Year ending January 31, 2022	819
Year ending January 31, 2023	464
Total operating lease payments	$ 3,550

Commitments and contingencies_2

Commitments and contingencies - Schedule of minimum lease payments (Detail) - USD ($) $ in Thousands	Oct. 31, 2019	Jan. 31, 2019
Commitments And Contingencies [Line Items]
2020 (Remaining three months)	$ 611
Year ending January 31, 2021	2,404
Year ending January 31, 2022	1,621
Year ending January 31, 2023	200
Total capital lease payments	4,836
Less amounts representing interest	(452)
Total capital lease payments, net of interest	4,384
Less current portion	(2,413)	$ (1,869)
Total capital lease payments, net of interest and current portion	$ 1,971	$ 2,401

Commitments and contingencies_3

Commitments and contingencies - Additional information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018
Commitments And Contingencies [Line Items]
Operating lease rent expense	$ 462	$ 453	$ 1,373	$ 1,350
Capital lease interest expense	$ 64	$ 78	$ 215	$ 190
Maximum [Member]
Commitments And Contingencies [Line Items]
Lease period	36 months		36 months
Minimum [Member]
Commitments And Contingencies [Line Items]
Lease period	30 months		30 months

Income taxes - Additional infor

Income taxes - Additional information (Detail)	9 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Income Tax Disclosure [Abstract]
Effective tax rate	0.00%	0.00%
U.S. statutory tax rate	21.00%

Net loss per share attributab_3

Net loss per share attributable to common stockholders - Schedule of earnings per share basic and diluted (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Oct. 31, 2019	Jul. 31, 2019	Apr. 30, 2019	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Oct. 31, 2019	Oct. 31, 2018
Numerator:
Net loss	$ (2,437)	$ (7,493)	$ (6,695)	$ (4,172)	$ (2,587)	$ (3,224)	$ (16,625)	$ (9,983)
Preferred stock dividend paid	0			0			(14,955)	0
Accretion of redeemable convertible preferred stock to redemption value	0			(9,236)			(56,175)	(20,962)
Net loss attributable to common stockholders	$ (2,437)			$ (13,408)			$ (87,755)	$ (30,945)
Denominator:
Weighted-average shares of common stock outstanding, basic and diluted	35,790,951			1,909,858			15,007,247	1,176,833
Net loss attributable to common stockholders	$ (0.07)			$ (7.02)			$ (5.85)	$ (26.30)

Net loss per share attributab_4

Net loss per share attributable to common stockholders - Schedule of antidilutive securities excluded from computation of earnings per share (Detail) - shares	9 Months Ended
	Oct. 31, 2019	Oct. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	6,873,284	31,243,853
Redeemable convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	0	25,311,535
Stock options to purchase common stock and restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	6,645,106	5,094,108
Warrants to purchase convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	0	581,798
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	228,178	256,411

Related party transactions - Ad

Related party transactions - Additional Information (Detail) - Affiliated Entity [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2019
Related Party Transaction [Line Items]
Recognized revenue	$ 1,223	$ 1,115	$ 4,098	$ 3,693
Accounts receivable	$ 1,277		$ 1,277		$ 598